
    
      participants receive EC/EP chemotherapy combined with Atezolizumab for 2 cycles, and the
      efficacy will be evaluated. If the efficacy evaluation is SD/PR/CR, concurrent
      chemoradiotherapy comined with EC/EP(2 cycles) + Atezolizumab will be initiated. After
      concurrent chemoradiotherapy + Atezolizumab, Atezolizumab was maintained until PD or
      intolerance or for at most 2 years.

      participants with brain metastases will receive radiotherapy for brain metastases during the
      first 2 cycles of chemotherapy.
    
  